JAK inhibitors for the treatment of vitiligo. Journal Abstract

JAK inhibitors for the treatment of vitiligo.

Publication Date: 2024 Mar

Full Text Sources

Elsevier Science

ClinicalKey

Authors

Shintaro Inoue; Tamio Suzuki; Shigetoshi Sano; Ichiro Katayama

Abstract

OBJECTIVE

Vitiligo is an autoimmune disease involving melanocyte-targeting T cells initiated by environmental and genetic factors. Steroids and tacrolimus have been used as topical treatments. Recently, novel topical agents targeting Janus kinase (JAK), a family of tyrosine kinases that regulates cytokine signaling, have emerged. Ruxolitinib is the first approved in vitiligo therapy. Furthermore, ritlecitinib is currently under clinical trials for oral treatment of active vitiligo. In this review, we discuss the possibility of topical JAK inhibitors as promising options for the treatment of vitiligo with regard to their mechanism of action, efficacy and safety.

Source

Journal of dermatological science

Pub Types(s)

Journal Article

Language

English

PubMed ID

38326166